Showing results (351-360 of 358) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 358 results.
BMC Medicine|May 16, 2024
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancerHuayi Li, Zikun Peng, Jianqing Zhu, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|December 9, 2022
The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective studyShaoqing Zeng, Jianhua Chi, Jiahao Liu, et al.
Frontiers in Medicine|May 16, 2022
Prognostic-Related Metabolic Score for Survival Prediction in Early-Stage Endometrioid Endometrial Cancer: A Multi-Center and Retrospective StudyZizhuo Wang, Kun Song, Jingbo Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II StudyLingfang Xia, Keqiang Zhang, Ying Tang, et al.
Frontiers in Medicine|November 8, 2021
Implications of Isolated Para-Aortic Lymph Node Metastasis in Endometrial Cancer: A Large-Scale, Multicenter, and Retrospective StudyWenting Li, Jie Jiang, Yu Fu, et al.
Nature Cancer|November 14, 2024
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneityJingyi Yang, Xiaole Song, Huankang Zhang, et al.
Frontiers in Medicine|May 2, 2022
Risk Factors and Prognosis of Early Recurrence in Stage I-II Endometrial Cancer: A Large-Scale, Multi-Center, and Retrospective StudyYingyu Dou, Kun Song, Yu Fu, et al.
Med (New York, N.Y.)|January 19, 2025
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trialHuayi Li, Yu Xu, Xiaofei Jiao, et al.
Pageof 36